Comparative Pharmacology
Head-to-head clinical analysis: EXTINA versus NYSERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXTINA versus NYSERT.
EXTINA vs NYSERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antifungal agent that inhibits the enzyme 14α-demethylase, blocking the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.
NYSERT is a fixed-dose combination of nystatin and sertaconazole. Nystatin, a polyene antifungal, binds to ergosterol in fungal cell membranes, disrupting permeability and causing cell death. Sertaconazole, an azole antifungal, inhibits lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis and accumulation of toxic methylsterols. Synergistic action provides broad-spectrum antifungal activity against Candida spp. and dermatophytes.
2.5% to 3.5% solution applied topically twice daily for 4 weeks.
10 mg orally once daily at bedtime, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 24-32 hours in adults, allowing once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Terminal elimination half-life approximately 20-25 hours in healthy adults; prolonged in hepatic impairment (up to 40 hours) and in elderly patients.
Primarily renal excretion of unchanged drug (approximately 80-90% of the absorbed dose), with minor hepatic metabolism and fecal elimination (<10%).
Primarily hepatic metabolism (CYP3A4) followed by biliary excretion of metabolites; ~60% fecal, ~30% renal (as metabolites), <5% unchanged in urine.
Category C
Category C
Antifungal
Antifungal